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ence is governed by a patchwork of poli-
cies that vary both between and within
countries. To assess how this atypical en-
vironment may have influenced this field’s
development, publication data were ana-
lyzed to evaluate the relative performance
of countries in the cumulative production
of hESC-related research articles versus
other areas of biomedical research. Over-
performing countries generally offered
permissive policy environments for hESC
research, while underperforming coun-
tries were characterized by protracted
policy debates and ongoing uncertainty,
regardless of their current policy environ-
ment.
The isolation and maintenance of
hESCs in their undifferentiated state, first
reported in 1998 (Thomson et al., 1998),
was an important but preliminary step to-
ward the potential development of novel
transplantation therapies and a route to-
ward a greater understanding of human
development. Yet because the tech-
niques used to isolate hESCs render
early human embryos unviable, this re-
search has generated substantial contro-
versy. Scientists are exploring alternative
derivation techniques that may mitigate
these ethical concerns (Takahashi et al.,
2007), but the development of hESC re-
search has been marked by ethical con-
troversy.
Policymakers in countries around the
world have balanced the long-term hope
presented by hESC research and the im-
mediate ethical controversy it creates in
a variety of ways. The result has been
the emergence of a regulatory patchwork
(Knowles, 2004) in which policies differ
substantially both between and within
countries and range from permissive to
restrictive (Salter, 2007). Some countries,
including the United Kingdom, Singapore,
and China, have actively embraced the
field, permitting the derivation of new
hESC lines both from embryos leftover af-
ter fertility treatment and through the useof the somatic cell nuclear transfer
(SCNT) under various oversight frame-
works. Other nations, such as Canada
and Taiwan, have adopted less permis-
sive policies that allow scientists to de-
velop new hESC lines from leftover em-
bryos but not through SCNT. Still others,
including Italy and Germany, have taken
a more restrictive approach, preventing
scientists from deriving new hESC lines
entirely and limiting them to work on cell
lines derived before a certain date or out-
side the country. The United States is an
unusual case. Federal funds—the funding
source for 63%of academic research and
development in the country (see National
Science Board, 2008)—can only be used
for studies on a small number of hESC
lines derived before August 9, 2001 (see
comments from G.W. Bush). Scientists
not using federal funding, in contrast,
face no national restrictions. These scien-
tistsmust comply with relevant state laws,
some of which support and some of which
restrict hESC research, and overcome lo-
gistical hurdles associated with ensuring
that no federal money goes toward
unapproved research (see report from
K. Kaplan and E. Cline).
As the United States illustrates, hESC
policies operate on a variety of levels. Na-
tional policies are prevalent, but state- or
province-level rules also matter, as do
international policies, such as those pro-
mulgated by the United Nations or
European Union (EU). Policy can address
a variety of activities related to hESC
science, including specific research
practices, research funding, and over-
sight mechanisms as well as intellectual
property or other issues related to the
commercialization of hESC science. The
analysis reported here focuses on hESC
policy directed toward the derivation of
new hESC lines, as many countries have
policies distinguishing among various
sources of embryos (see http://www.
hinxtongroup.org/ for a current listing of
country policies), but should be inter-Cell Stempreted in light of the full range of possible
hESC policies (Salter, 2007).
Given the public interest and political
salience of this field, it is not surprising
that interest in the impact of this atypical
policy environment has also increased.
Two initial reports focused on the United
States. By comparing data sets of
hESC-related publications with relevant
controls, these analyses both concluded
that the United States was lagging in the
production of hESC-related research
publications (Levine, 2005; Owen-Smith
and McCormick, 2006). More recently,
two additional reports have examined
the development of hESC science
through the lens of research publications
in the field (Guhr et al., 2006; Winston,
2007). These reports yield general insight
into the development of hESC research,
by identifying countries actively produc-
ing hESC articles, but do not compare
this performance with other fields and
cannot attribute it to the policy environ-
ment in any systematic manner.
Although the hESC research policy
environment has received considerable at-
tention, policy is one of many factors that
can influence research output. Some of
these factors operate at the level of the
individual scientist. These include scien-
tists’ personal preferences toward specific
fields, research questions or methodolo-
gies, their career ambitions (Garner,
1979), and their networks of colleagues
and collaborators (Blumenthal et al.,
1996). Other factors influence the research
enterprisemore broadly. These include the
differences in the set of institutions in-
volved in the oversight and production of
new knowledge (Nelson, 1993), priorities
of specific funding agencies (Braun,
1998), historic and projected economic
growth, public views toward scientific
inquiry (Gaskell et al., 2005), linkages
between academic and industry science
(Gulbrandsen and Smeby, 2005), and the
systems created to evaluate and reward
scientists (Geuna and Martin, 2003).Cell 2, June 2008 ª2008 Elsevier Inc. 521
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The cumulative share of publications through 2006 citing the initial hESC paper, the initial RNAi paper, and
the average cumulative share of articles citing each of the 50 randomly selected control articles are shown
for each of 16 countries. Absolute and relative differences between a country’s share of publications re-
lated to either hESCs or RNAi and the control set are shown. Shaded cells indicate that the absolute dif-
ference is significant at the p < 0.005 level, using two-sided t tests. All countries that produced at least 1%
of publications in one of the three sets are shown, and countries are sorted by their absolute performance
in hESC-related research. n = 1,112 (hESC set), 1,951 (RNAi set), and 19,096 (control set).Here the focus is on comparing the pub-
lication output of individual countries in re-
search related to hESCs with their output
related to another emerging, but less con-
tentious, field and in biomedical research
more broadly. This analysis has two goals.
First, it aims to identify which nations are
overperforming and which are underper-
forming in hESC science. Second, it seeks
to increase our understanding of the role
played by the policy environment and
other hESC-specific factors in the interna-
tional development of this field.
Multiple considerations led this analysis
to focus on the impact of country-specific
factors. First, despite the increasingly
global nature of science, approximately
80% of science and engineering articles
published across all fields in 2005 were
produced by scientists in a single country
(see National Science Board, 2008). Sec-
ond, even when collaborative research is
conducted or transnational research poli-
cies are enacted, national laws play an im-
portant role. This prominence of national
policies is visible, for instance, in recent
EU discussions over hESC research, in
which divergent preferences at the coun-
try level have hindered the creation of
coherent EU-wide funding policies.
As peer-reviewed research articles are
a major output of basic biomedical re-
search, this analysis relies on publication
data to address these questions. Specifi-522 Cell Stem Cell 2, June 2008 ª2008 Elsevcally, three sets of research articles were
developed and compared. The first set
contains all research articles citing the ini-
tial hESC paper (Thomson et al., 1998).
Many of the articles in this set represent
follow-on research using hESCs. Others
represent research in a range of related
fields, and a few represent reviews or
commentaries that slipped through the
screening process. For this reason, this
analysis focuses on ‘‘hESC-related’’ re-
search rather than hESC research exclu-
sively. The second set contains all re-
search articles citing the initial RNA
interference (RNAi) paper (Fire et al.,
1998). RNAi is another important, but
much less contentious, biomedical re-
search tool. Like hESCs, RNAi has both
immediate applications as a research
tool and potential clinical applications.
The third set is designed to represent bio-
medical research more generally. It was
constructed through a two-step process.
Initially, 50molecular biology andgenetics
articles from 1998 were randomly se-
lected from the top 1% of most-cited
articles in this field. Some of these articles
defined new subfields or reported new re-
search tools, similar to the initial hESC or
RNAi articles. Others reported important
advances in more established subfields.
All generated substantial follow-up re-
search. All research articles citing each
of these 50 articles were retrieved. Eachier Inc.article in these three sets was then as-
signed to a single country on the basis of
the corresponding author. Compared to
previous analyses (Levine, 2005; Owen-
Smith and McCormick, 2006), the larger
data set used in this study permits an
assessment of individual country perfor-
mance in hESC-related research. Addi-
tionally, the time-matched nature of the
three sets (all source articles were pub-
lished in 1998) reduces concerns about
the ongoing globalization of biomedi-
cine—notably the well-documented de-
cline in the total share of research pro-
duced by U.S. scientists (National
Science Board, 2006)—influencing the
results. (More methodological details and
a list of the 50papers that formed thebasis
of the control set are included in the Sup-
plemental Data available online.)
To assess research output at the coun-
try level, Figure 1 shows the cumulative
share of research publications between
1998 and 2006 in the three sets for 16
countries—all countries that made up at
least 1% of one of the three sets. To iden-
tify significant over- and underperformers,
each country’s cumulative share of
hESC-related research and RNAi-related
research was compared with its average
cumulative share of research in the con-
trol set using two-sided t tests. Because
the use of share data introduced an addi-
tional constraint—the requirement that
the cumulative share for all countries
sum to 100%—a conservative significan-
ce threshold of p < 0.005 was used. Abso-
lute differences meeting this threshold are
shaded in Figure 1. Nine countries show
statistically significant differences for
hESC-related research, compared with
four countries for RNAi-related research.
Notably, the top four overperforming
countries in hESC-related research all
have long had public policies that support
this field, by permitting the derivation of
new hESC lines from embryos leftover af-
ter fertility treatment and through SCNT.
These countries have also complemented
their policies with government support for
research in this field (Normile and Mann,
2005; Vogel, 2002; see also reports from
W. Arnold and T. Webb). The fifth country,
Australia, adopted a policy permitting sci-
entists to derive new hESC lines from em-
bryos created but no longer needed for
fertility treatment in 2002. This policy ex-
plicitly banned SCNT. Following an
extensive independent review, a revised
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Absolute over-/underperformance compared to the control set is shown for hESC-related research on the x axis and RNAi-related research on the y axis. Blue
squares indicate countries with significant differences for both hESC- and RNAi-related research, red diamonds indicate countries with significant differences for
only hESC research, and green circles indicate countries with significant differences for only RNAi-related research. Black triangles indicate countries from Figure
1 that did not have significant differences for either technology.policy permitting scientists to use SCNT
with human eggs under a detailed over-
sight system was adopted in December
2006 (Sinclair and Schofield, 2007).
The relationship between underper-
formance and the policy environment is
less clear, although the countries under-
performing in hESC-related research gen-
erally lack either permissive policies,
complementary government support, or
both. The United States, though still the
largest single producer of hESC-related
research publications, is the largest
underperformer by the metric used here.
Scientists in the United States produced
36% of hESC-related research compared
with 47% of RNAi-related research and
46% of research in the control set. This
significant underperformance suggests
that federal funding restrictions may
have influenced the amount of hESC re-
search conducted by U.S. scientists, de-
spite the presumably positive impact of
the emergence of state support for this
field. Because privately funded research
is not restricted in theUnited States, theseresults may also reflect a shift of U.S.
hESC research into the private sector,
where scientists have less incentive to
publish. This group of underperformers
also contains Japan, where controversy
over hESC research policies and bureau-
cratic hurdles to acceptable projects have
reportedly hindered research (see N. Na-
katsuji) and France, where hESC research
was initially blocked by a 1994 law that
has subsequently been slightly, but only
temporarily, relaxed (see report by S.
Webb and T. Pain). Several of these
underperforming countries have policies
today that permit the derivation of new
hESC lines from leftover embryos, and
Japan has announced plans to permit
SCNT. However, in each of these coun-
tries, the policy debate has been pro-
tracted, forcing hESC scientists to navi-
gate an uncertain policy environment.
Examination of Figure 1 suggests that
countries’ shares of research related to
hESCs differ more from the control set
than do their shares of research related
to RNAi. Chi-square tests of homogene-Cell Stemity, comparing the raw count of articles
by country in the hESC- and RNAi-related
sets with the average count of articles by
country from the control set, confirmed
this observation. Specifically, these tests
rejected the null hypothesis that the un-
derlying country distributions of hESC-re-
lated research and research in the control
set were the same (ChiStat = 66, df = 16,
p = 5.2 e8) but failed to reject the parallel
null hypothesis for the comparison be-
tween RNAi-related research and the
control set (ChiStat = 18, df = 16, NS).
Although Figure 1 highlights over- and
underperforming countries in hESC-
related research, it is not necessarily the
case that these data reflect field-specific
considerations. They may instead reflect
more systematic influences on the scien-
tific enterprise. To distinguish the influ-
ence of hESC-specific factors from more
systematic considerations, Figure 2 com-
bines country-level performance for both
hESC- and RNAi-related research. When
performance for both hESC- and RNAi-
related research varies in tandem, itCell 2, June 2008 ª2008 Elsevier Inc. 523
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play an important role. In contrast, coun-
tries that show variation in performance
for one field, but not the other, likely re-
flect field-specific considerations.
Research performance in three coun-
tries—China, Japan, and France—ap-
pears to reflect systematic characteristics
influencing the development of new bio-
medical technologies. China is the only
country to significantly overperform in
both fields. This likely reflects China’s
rapid economic growth and increasing in-
vestment in science and technology (for
a review and details on the oversight of
hESC research in China, see Salter et al.,
2006). Japan and France, in contrast,
underperform in both fields. Although
bureaucracy and field-specific policies
may be hindering hESC-related research
in these countries, this systematic under-
performance suggests that other factors,
suchasorganizational structures forpublic
science that are less conducive to explor-
ing emerging technologies (Clark, 1995;
Whitley, 2003), may also be important.
Six countries show significant differ-
ences in their performance in hESC-
related research but do not show similar
differences for RNAi-related research.
Policies specific to hESC research or
other field-specific factors may explain
this observed underperformance in the
United States and Switzerland and over-
performance in the United Kingdom, Is-
rael, Singapore, and Australia. The scale
of overperformance is particularly notable
in Singapore and Israel, where focused
hESC research efforts appear to have
paid dividends. In relative terms, Israel’s
share of hESC-related research is 6.5
times larger that its share of the control
set, while Singapore’s share of hESC-re-
lated research is 8.8 times larger that its
share of the control set.
By systematically comparing country
performance in hESC-related research
with performance in another emerging,
but less contentious, field and biomedical
researchmore broadly, this analysis offers
new insight into the international develop-
ment of hESC science. Six countries
showed significant performance differ-
ences that were specific to this field.524 Cell Stem Cell 2, June 2008 ª2008 ElsevOverperforming countries typically had
long-standing supportive policies, while
underperforming countries have adopted
a range of policies but typically offer
research environments characterized by
protractedpolicydebatesanduncertainty.
These results suggest that policy, broadly
defined, has played andwill likely continue
to play an important role in shaping the in-
ternational development of hESC science.
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